Eriodictyol Clinical Trials

Size	Price	Qty
1mg	USD 147
5mg	USD 397

Clinical Trials

A completed clinical trial sponsored by an academic institution, the University of Glasgow, evaluated the physiological and pharmacokinetic profiles of eriodictyol in healthy subjects. Operating under a non-applicable trial phase, the investigation explored how endurance training status in athletes affects the oral bioavailability of flavanones. Consequently, clinical research on eriodictyol remains limited to baseline metabolic studies in healthy cohorts rather than evaluations for specific therapeutic conditions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02627547	Completed	Healthy	University of Glasgow	2013-09	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Eriodictyol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a natural flavonoid derived from yerba santa, eriodictyol directly scavenges reactive oxygen species and modulates pro-inflammatory signaling cascades, thereby dampening oxidative stress and suppressing cellular inflammatory responses. This fundamental antioxidant and anti-inflammatory activity underpins its physiological bioactivity and systemic absorption parameters evaluated in healthy individuals.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).